肠道ACE2水平改变与炎症性肠病炎症、疾病严重程度及抗细胞因子治疗反应相关
该研究利用4个小肠和2个结肠队列(n=495;溃疡性结肠炎n=387;非炎症性肠病n=94)的转录组数据,分析ACE2与人口学、疾病活动及预后的关系,并评估3项临床试验中抗细胞因子治疗对ACE2的影响。结果显示小肠克罗恩病ACE2降低、结肠溃疡性结肠炎ACE2升高,均与炎症和严重疾病相关,抗细胞因子治疗可恢复ACE2表达。
要点
- 小肠克罗恩病ACE2水平降低,结肠溃疡性结肠炎ACE2水平升高。
- 活动性炎症和后续严重疾病与ACE2改变相关。
- 抗细胞因子治疗可恢复ACE2表达,应答者尤为明显。
核心结论
- 炎症性肠病中小肠ACE2降低而结肠ACE2升高,与炎症和严重疾病相关,抗细胞因子治疗后恢复正常,提示ACE2相关生物学在部位间存在区隔化。
研究设计与样本
- 利用4个小肠和2个结肠组织队列的RNA测序或微阵列转录组数据(n=495;溃疡性结肠炎n=387;非炎症性肠病n=94),分析ACE2与人口学、疾病活动及预后的关系,并评估3项临床试验中抗肿瘤坏死因子和抗白介素-12/白介素-23治疗对ACE2的影响,采用单因素和多因素回归模型。
主要发现
- 与非炎症性肠病对照相比,小肠克罗恩病ACE2水平降低,结肠溃疡性结肠炎ACE2水平升高。
- 小肠ACE2升高与年龄和体重指数升高相关,这些人口学特征与COVID-19不良结局相关。
- 在克罗恩病中,后续发生复杂疾病的小肠ACE2降低;在溃疡性结肠炎中,活动性疾病和后续需要抗肿瘤坏死因子挽救治疗的患者结肠ACE2升高。
- 活动性克罗恩病和溃疡性结肠炎的小肠和结肠ACE2表达可被抗细胞因子治疗恢复,应答者中尤为明显。
临床怎么用
- 作者认为抗细胞因子治疗恢复ACE2表达在SARS-CoV-2感染背景下可能重要,或可部分解释接受抗细胞因子治疗的炎症性肠病患者COVID-19发病率降低的报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The host receptor for severe acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small bowel (SB). Our aim was to identify factors influencing intestinal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls. METHODS: Using bulk RNA sequencing or microarray transcriptomics from tissue samples (4 SB and 2 colonic cohorts; n = 495; n = 387 UC; n = 94 non-IBD), we analyzed the relationship between ACE2 with demographics and disease activity and prognosis. We examined the outcome of anti-tumor necrosis factor and anti-interleukin-12/interleukin-23 treatment on SB and colonic ACE2 expression in 3 clinical trials. Univariate and multivariate regression models were fitted. RESULTS: ACE2 levels were consistently reduced in SB CD and elevated in colonic UC compared with non-IBD controls. Elevated SB ACE2 was also associated with demographic features (age and elevated body mass index) associated with poor coronavirus disease 2019 outcomes. Within CD, SB ACE2 was reduced in patients subsequently developing complicated disease. Within UC, colonic ACE2 was elevated in active disease and in patients subsequently requiring anti-tumor necrosis factor rescue therapy. SB and colonic ACE2 expression in active CD and UC were restored by anti-cytokine therapy, most notably in responders. CONCLUSIONS: Reduced SB but elevated colonic ACE2 levels in IBD are associated with inflammation and severe disease, but normalized after anti-cytokine therapy, suggesting compartmentalization of ACE2-related biology in SB and colonic inflammation. The restoration of ACE2 expression with anti-cytokine therapy might be important in the context of severe acute respiratory syndrome coronavirus 2 infection and potentially explain reports of reduced morbidity from coronavirus disease 2019 in IBD patients treated with anti-cytokines.
引用
- Potdar AA, Dube S, Naito T, et al. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease. Gastroenterology. 2020. PMID: 33160965. doi:10.1053/j.gastro.2020.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。